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Abstract:  Two experiments were conducted to determine: 1) whether the adult male 
transgenic sickle cell mouse (Tg58 × Tg98; TSCM), exhibits the patterns of reproductive 
endpoints (hypogonadism) characteristic of men with sickle cell disease (SCD) and 2) 
whether hydroxyurea (HU) exacerbates this condition. In Experiment 1, blood samples 
were collected from adult age-matched TSCM and ICR mice (ICRM) (N = 10/group) for 
plasma testosterone measurements. Subsequently, mice were sacrificed, testes excised and 
weighed and stored spermatozoa recovered for the determination of sperm density, 
progressive motility and percentage of spermatozoa with normal morphology. In 
experiment 2, adult male TSCM were orally treated with 25 mg HU/kg body weight/day 
for 28 or 56 days. Control mice received the vehicle for HU (saline) as described above. At 
the end of the treatment periods, blood samples were collected for quantification of 
circulating testosterone. Subsequently, mice were sacrificed, testes and epididymides were 
recovered and weighed and one testis per mouse was subjected to histopathology. Stored 
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spermatozoa were recovered for the determination of indices of sperm quality mentioned in 
Experiment 1. Testis weight, stored sperm density, progressive motility, percentage of 
spermatozoa with normal morphology and plasma testosterone concentrations of TSCM 
were significantly lower by 40, 65, 40, 69 and 66%, respectively than those of ICRM. 
These data indicate that adult TSCM used in this study suffered from hypogonadism, 
characteristically observed among adult male SCD patients. In Experiment 2, HU 
treatment significantly decreased testis weight on day 28, (0.09 ± 0.004g) that was further 
decreased on day 56 (0.06 ± 0.003g; treatment x time interaction) compared with controls 
(day 28, 0.15 ± 0.01g; day 56, 2, 0.16 ± 0.01g). Concomitant with a 52% shrinkage 
(P<0.001) in area of testes in 56 days of HU treatment, testes from HU-treated TSCM 
exhibited significant atrophic degeneration in the seminiferous tubules compared with 
controls. Furthermore, treated TSCM had only Sertoli cells and cell debris remaining in 
most of the seminiferous tubules in comparison with controls. Leydig cell prominence and 
hyperplasia were more evident (P<0.05) in the steroidogenic compartments of testes of 
HU-treated TSCM compared with controls. However, plasma testosterone concentrations 
were reduced by HU treatment (P<0.05; treatment x time interaction) compared with 
controls on the two time periods studied. Epididymides from HU-treated TSCM sustained 
a 25% shrinkage (P<0.05), along with 69 (P<0.005) and 95% reduction (P<0.005), in 
stored sperm density and sperm progressive motility (treatment x time interaction P<0.05), 
respectively on day 56 of treatment compared with controls. These data demonstrate that 
TSCM used in this study exhibited SCD-induced hypogonadism, thus authenticating their 
use for studying the effect of HU on male reproductive endpoints observed in SCD 
patients. Secondarily, our data show that HU treatment exacerbated the already SCD-
induced hypogonadism to gonadal failure. 
Keywords: Hydroxyurea; Hypogonadism; testicular failure; transgenic sickle cell mouse; 
Sickle cell disease; spermatozoa, testosterone. 
 
 
1. Introduction 
 
Sickle cell anemia is one of the most common human autosomal recessive disorders caused by a 
mutational substitution of thymine for adenine in the sixth codon (GAG to GTG) of the  globin gene 
on chromosome 11p [1]. This mutation results in the encoding of valine rather than glutamic acid at 
position 6 of the  globin chain [1]. Sickle cell disease (SCD) is characterized by a painful vaso 
occlusive crisis resulting from the blockage of capillaries by the interaction of sickle erythrocytes, 
leukocytes, platelets and plasma proteins with vascular endothelium [1]. Compared with children with 
normal hemoglobin, the onset of the
 adolescent growth spurt is usually delayed in SCD patients by 1.4 
years, with no significant sex difference [2]. However, men carrying homozygous genes for SCD are 
more prone to delayed somatic and sexual development than their female counterparts [3]. 
Additionally, male patients suffer from episodes of priapism, a persistent painful erection of the penis 
unassociated with sexual stimulation or desire and detumescence does not occur following ejaculation 
[4]. Furthermore, male SCD patients also suffer from repeated testicular infarction [5] that can impair Int. J. Environ. Res. Public Health 2009, 6          
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testicular function. Testicular index, indices of semen quality and serum testosterone concentrations of 
male SCD patients are generally lower than those of men with normal hemoglobin even though 
circulating follicle stimulating hormone (FSH), luteinizing hormone (LH) and prolactin (PRL) are 
comparable, indicating hypogonadism among SCD patients [6].  
Currently there is no cure for SCD. However, the FDA has recently approved hydroxyurea (HU), an 
antineoplastic agent, for the treatment of SCD [7]. Hydroxyurea increases fetal hemoglobin which has 
a higher oxygen carrying capacity and does not undergo sickling under low oxygen tension, thus 
improving some aspects of quality of life in patients suffering from moderate to severe SCD [8,9]. It 
was only recently that Cokic et al. [10] presented results that provided the first explanation of how HU 
increases fetal hemoglobin levels in treated patients. Specifically, fetal hemoglobin increases in 
response to activation of soluble guanynyl cyclase (sGC) by HU-derived nitric oxide. As an 
antineoplastic agent, the specific action of HU is on ribonucleotide reductase whose action is to reduce 
ribonucleotides to deoxyribonucleotides. Hydroxyurea impedes the latter reaction and limits DNA 
biosynthesis. This makes HU an S-phase-specific cytotoxic and antineoplastic agent that interrupts the 
cell cycle at the G1 and S phases [11]. It is conceivable that HU-induced inhibition of DNA replication 
in treated SCD patients can compromise the function of organs like the testis and epididymis that rely 
on DNA transcription. Interestingly, studies with laboratory animals indicate that treatment with HU 
impairs spermatogenesis, resulting in testicular atrophy [12-14], a reversible
 decrease in sperm count, 
motility [12-16] and abnormal sperm morphology [13,15-17]. Furthermore, HU alters the chromatin 
structure of preleptotene spermatocytes [13,14] and increases apoptosis in spermatogonia and
 early 
spermatocytes with no apparent adverse effect on stem spermatogonia [18]. It could therefore be 
surmised that the possibility for the resumption of spermatogenesis exists after the withdrawal of HU 
treatment. The common denominator among the aforementioned animal studies is that the doses of HU 
used in these studies were several times the dose range used for treating patients with SCD.  
A case-study
 reported follow-up semen analyses for a 29-year
 old SCD patient under HU treatment 
[19].
  After a normal semen analysis at the beginning of therapy and
 one month later, the patient 
became azoospermic at six months, and
 remained in that state one month later. Ten months after the 
cessation of HU treatment,
 another semen analysis showed partial recovery of spermatogenesis.
 Thus 
an adverse effect of hydroxyurea was suspected in this
  case of transient and partially reversible 
azoospermia. In a retrospective review of four adult men who had semen analyses during HU therapy, 
three cases after cessation of treatment suggested that HU generally reduces sperm counts, motility and 
increased incidence of abnormal sperm morphology. Cessation of HU in one HU-induced azoospermia 
resulted in the resumption of spermatogenesis, however in two of the three cases with HU-induced 
altered sperm parameters, sperm morphology and motility remained impaired [20]. Despite the 
suggestion by these two human studies that HU could adversely impact fertility indices; they constitute 
case studies that lack sufficient numbers to warrant statistical scrutiny and inferences.  
Recently, Berthaut et al. [21] showed in a retrospective study that SCD-induced hypogonadism was 
exacerbated by HU treatment. This is the first study in humans that attempted to study the effect of a 
clinically relevant dose of HU (20–30
 mg/kg body weight/day) on fertility endpoints of male SCD 
patients. However, because of its retrospective nature, this study is plagued by a lack of design and 
powerful statistical tools that would have resolved some of the subtle differences missed. Kopsombut 
et al. [22] showed that treatment of adult normal male mice (ICR strain) with a clinically relevant dose Int. J. Environ. Res. Public Health 2009, 6          
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of HU (30 mg/kg) for 30 days, significantly reduced testis weight, stored sperm density and 
progressive motility. Testis weight and stored sperm parameters were not reversed even at the 4th 
month post withdrawal of HU treatment. This is the only designed study that showed that a clinically 
relevant dose of HU used for the treatment of SCD albeit conducted in normal mice, adversely affects 
testis and epididymal function. Consequently, the use of an appropriate transgenic SCD animal model 
for the determination of the link between SCD and HU treatment on male fertility indices is warranted. 
The transgenic SCD mouse model used in this study is one that was developed by Popp et al. [23] 
from Tg58/β-thal and Tg98/β-thal mice, out of constructs of the human α (hα) and human β
S Antilles  
(hβ
S Antilles) genes [24]. The Hb S Antilles transgene insertions from Tg58/β-thal and Tg98/β-thal mice 
were bred into the genome of mice with high oxygen affinity referred to as MHOAH mice to produce 
M-Tg58Ru and M-Tg98Ru mice, respectively. Subsequently, these mice were mated to each other to 
produce a doubly homozygous Tg58 × Tg98 line of Hb S Antilles transgenic mice hereafter referred to 
as transgenic sickle cell mice (TSCM). These mice produce sickle shaped red blood cells (RBCs), 
exhibit reticulocytosis, elevated white blood cell count, lung and kidney pathologies commonly found 
in sickle cell patients [23]. However, the incidence of hypogonadism characteristic of men with SCD 
was not studied in these mice. The objectives of this study were: 1) to determine whether TSCM is a 
suitable transgenic mouse model for studying the link between SCD and hypogonadism; and 2) to 
determine whether a clinically relevant dose of HU used for treating SCD exacerbates SCD-induced 
hypogonadism.  
 
2. Materials and Methods 
 
2.1. Animals 
 
Acclimatized adult male ICR mice (ICRM; 7-8 weeks of age) and age-matched TSCM were housed 
by strain in groups of four in polyethylene cages. Mice were maintained in an environmentally 
controlled room with 12 hour light: 12 hour dark cycle, 22
C and humidity range of 50 to 60% and 
allowed ad libitum access to commercial pelleted mouse chow and water.  
 
Experiment 1 
 
The rationale for conducting this experiment was to determine whether Tg58 × Tg98 line of Hb S 
Antilles transgenic mouse is a suitable model for studying the effect of a clinically relevant dose of HU 
on fertility of male SCD patients. To accomplish this, acclimated age-matched adult male ICRM and 
TSCM (N = 10/strain) were anesthetized with isoflurane between 1,400 and 1,600 hr, following which 
mid-ventral laparotomy was performed to permit blood collection via inferior vena cava puncture into 
heparinized tubes. Plasma was harvested from each sample by centrifugation at 1,500-x g for 10 
minutes at 4
C and stored at -20
C until assayed for testosterone concentrations. Testes were 
subsequently recovered and weighed. Cauda epididymides excised and stored spermatozoa were 
recovered as detailed in Archibong et al. [25] in Whitten’s medium [26] pre-equilibrated at 37
C in an 
atmosphere of 5% CO2 in air under washed mineral oil. After 15 min incubation at the above Int. J. Environ. Res. Public Health 2009, 6          
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mentioned conditions, sperm density, progressive motility and morphology were determined in 
homogenous sperm suspensions. 
 
2.2. Stored Sperm Density 
 
The density of stored spermatozoa was determined by hemocytometric counting after sperm 
suspensions were each subjected to 20X dilution with an immobilizing diluent (50 g sodium 
bicarbonate, 10 mL of 40% formaldehyde solution and 0.25 g trypan blue dissolved in 1 liter of  
water [22]. Stored sperm density per sperm suspension was based on two counts of 100 cells each.  
 
2.3. Progressive Sperm Motility 
 
Progressive sperm motility was determined microscopically with a phase contrast microscope 
(magnification = 400X; Olympus BX 41). The percentage of progressively motile spermatozoa per 
sperm suspension was based on two counts of 100 cells each.  
 
2.4. Sperm Morphology 
 
Stored spermatozoa were stained with modified Papanicolaou staining kit (Spermac, Stain 
Enterprises, S. Africa) according to the manufacturer’s instructions and sperm morphologies were 
assessed according to the criteria of Filler [27].  
 
2.5. Testosterone Radioimmunoassay (RIA) 
 
Plasma samples were analyzed for testosterone concentrations by RIA validated in our laboratory. 
The sensitivity of testosterone assay was 2 pg/tube and the intra- and inter-assay coefficients of 
variation were 8.5 and 8.7%, respectively [28].  
 
Experiment 2 
 
The rationale for conducting this experiment was to assess whether HU exacerbates SCD- induced 
hypogonadism. Adult TSCM were randomly assigned to a treatment or a control group   
(N = 12/group). Treatment consisted of 25 mg HU (Sigma Chemical Co., St. Louis, MO, USA)/kg 
body weight via oral gavage for 28 (N = 6) or 56 (N = 6) days, to assess HU toxicity to testis and 
epididymal function before or after completion of a spermatogenesis cycle, respectively. The 
maximum interval between type A spermatogonium and its release as mature spermatozoa from the 
seminiferous tubule is 35.5 days [29]. Transgenic sickle cell mice in the control group were 
administered with saline (vehicle for HU) as described for treated mice and equal numbers were 
sacrificed along with HU-treated mice on the respective days mice in the latter group were sacrificed. 
All mice were weighed monthly and examined daily for normal activity and behavior, coat condition 
and normal feed and water intake. At the end of the treatment periods, mice were anesthetized, blood 
samples collected and plasma recovered and assayed for testosterone content as described in Int. J. Environ. Res. Public Health 2009, 6          
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Experiment 1. Furthermore, testes and epididymides were recovered and weighed and one 
testis/mouse/treatment and control group (N = 5/group) sacrificed on day 56 of HU treatment was 
prepared for histopathology. Assessments of testes from control and HU-treated TSCM included the 
evaluation of gonadal dimensions (length × width [L × W] of largest step section; sq mm), integrity of 
the seminiferous tubules (normal or atrophic/degenerative) and Leydig cell hyperplasia and 
prominence. Cauda epididymides of control and treated TSCM were processed for the recovery of 
stored spermatozoa as detailed in Archibong et al. [25].  
 
2.6. Histopathology 
 
Testes were fixed in Bouin’s solution for 24 to 72 hours prior to histological preparation according 
to the method of Lunstra et al. [30]. Briefly, fixed testis pieces from HU-treated and control TSCM 
were washed in PBS (1 × 1 h), dehydrated through graded ethanol (50, 70, 80, 90, 100; 2 × 1 hr each), 
cleared in xylene (2 × 1 h; Sigma, St. Louis, MO, USA), infiltrated with paraffin wax (60°C; 4 × 1 hr), 
and embedded in paraffin wax. Serial sections (5 µm) were subsequently cut from the middle of each 
testis preparation. Sections were dried overnight onto glass slides at 37
°C and stored at room 
temperature until processed for histology. Sections were deparaffinized in Microclear (2 × 5min; 
Micron Environmental Industries, Fairfax, VA, USA) and rehydrated through graded ethanol   
(2 × 100%, 2 × 95%, and 1 × 70%). Thereafter, sections were rinsed thoroughly in water, stained with 
hematoxylin, dehydrated, cleared in Microclear and mounted using DPX mounting media (Fluka). 
Stained histological preparations were evaluated at 50x magnification using a Leitz microscope 
coupled to a computerized morphometric planimetry system (Bioquant Nova 2000 Advanced Image 
Analysis, R&M Biometrics, Nashville, TN, USA) for structural alterations in the seminiferous tubules 
and Leydig cells. The stages of structural alterations in seminiferous tubules were classed as normal, 
minimally atrophic/degenerative, moderately atrophic/degenerative or severely atrophic/degenerative 
and assigned the following numerical scores: 1.1, 2.1, 3.1 or 4.1, respectively. Leydig cells were 
classed as normal, minimally prominent, moderately prominent, or severely prominent and assigned 
numerical scores similar to those of seminiferous tubules. 
 
2.7. Stored Sperm Progressive Motility and Density 
 
Spermatozoa were recovered from the cauda epididymides of each HU-treated and control TSCM 
on day 28 or 56 of treatment and the density and progressive motility of stored spermatozoa were 
evaluated as described in Experiment 1.  
 
2.8. Statistical Analyses 
 
Data on testis weight, stored sperm density and progressive motility, stored spermatozoa with 
normal morphology and plasma testosterone concentrations in Experiment 1 were compared by 
unpaired “t” test. Data collected in Experiment 2 (monthly body weight, testis and epididymal weight, 
stored sperm density and motility and plasma testosterone concentrations) were analyzed by Two-way 
analysis of variance and differences among means were tested for significance with unpaired “t” tests. Int. J. Environ. Res. Public Health 2009, 6          
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The scores for stages of structural damage to the seminiferous tubules and Leydig cell prominence 
were compared with unpaired “t” tests [31].  
 
3. Results 
 
The reproductive characteristics of ICRM and TSCM are presented in Table 1. The reproductive 
system of TSCM used in this study was mature and functional based on the presence of mature 
spermatozoa in the cauda epididymides. However, testis of TSCM weighed less (P<0.025) than those 
of ICRM. Similarly, stored spermatozoa recovered from TSCM were fewer (P<0.005), less 
progressively motile (P<0.005) and had fewer (P<0.005) spermatozoa with normal morphology than 
those recovered from their ICRM counterparts. Furthermore, plasma testosterone concentrations were 
lower (P<0.05) in TSCM compared with ICRM.  
 
Table 1. Comparison of Fertility Indices (Mean ± SE) of TSCM (Tg58 x Tg98) and ICRM. 
Item TSCM ICRM 
Testis wt (g)  0.15 ± 0.01**  0.25 ± 0.01 
Stored sperm density (x 10
6)  14 ± 3.6***  40.3 ± 3.6 
Sperm progressive motility (%)  39.0 + 8.7***  65.13 + 2.3 
Sperm with normal morphology (%)  14.7 ± 2.3***  48.0 ± 5.1 
Plasma testosterone concentrations (ng/mL)  2.4 ± 0.72*  7.0 ± 0.75 
* P<0.05; ** P<0.025; ***P<0.005 
 
Monthly body weights of control and HU-treated TSCM were similar during the two months of 
this study, suggesting that treatment of TSCM for 28 to 56 days with the clinically relevant dose of HU 
used for treating patients with sickle cell disease did not affect body weight. Mean monthly weights 
(Mean + SE) of TSCM increased from 30.43 ± 0.99 to 32.7 ± 0.89 and 34.37 ± 0.88 during the first 
and second month of treatment, respectively among control TSCM, similar to increases in body 
weights that occurred among HU-treated TSCM from 30.88 ± 0.93 at the onset of treatment to   
32.01 ± 0.99 and 33.76 ± 0.96 g during the first and second month of treatment, respectively. Even 
though the mean body weights of TSCM was not affected by the regimen of HU used in this study, it 
adversely affected the testis of treated compared with control mice. Hydroxyurea treatment cause a 
40% decrease in testis weight on day 28, followed by a further 22% decrease in this organ by day 56 of 
treatment (treatment x time interaction; P<0.05) compared with control TSCM (Figure 1). Table 2 
depicts the dimension and histological characteristics of testes from HU-treated versus control TSCM. 
The area of testes from HU-treated mice shrank to 5.2 ± 0.2 sq mm (range, 5.0 to 6.0 sq mm) in 56 
days of treatment, approximately 52% reduction (P<0.001) compared to their control counterparts 
(10.8 ± 0.9; range, 7.5 to 12.0). Our results also show that testes from HU-treated TSCM exhibited 
atrophic/degenerative seminiferous tubules (P<0.001) with only Sertoli cells and cell debris remaining 
in most of the tubules in comparison with controls. Furthermore, Leydig cell prominence and 
hyperplasia were more evident (P<0.05) in the testes of HU-treated TSCM compared with controls. 
The above mentioned pathological changes are depicted in the photomicrographs of testis histologies 
of HU-treated and control mice (Figure 2). In comparison with controls, epididymides from HU-Int. J. Environ. Res. Public Health 2009, 6          
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treated TSCM weighed approximately 25% less (treatment x time interaction P<0.05) on day 56 of 
treatment (Figure 3). The HU-induced shrinkage in this organ was followed concomitantly with 
approximately 69% reduction in the ability of the cauda epididymis to store matured spermatozoa 
(Figure 4; treatment x time interaction; P<0.005) compared with controls. Furthermore, epididymides 
from HU-treated TSCM sustained about 95% reduction in their ability to impartment motility to 
matured spermatozoa (Figure 5; treatment x time interaction; P<0.005) compared with those of 
controls. Plasma concentrations of testosterone (ng/mL) were lower (treatment x time interaction; 
P<0.05) in HU-treated TSCM versus those of their control counterparts (Figure 6). 
 
Figure 1. Mean Testis Weight of HU-treated Versus Control TSCM. 
 
Table 2. Adverse effects of HU (25 mg/kg)-treated TSCM after 56 days. 
 
Findings 
 Control TSCM  HU Treated TSCM 
#1 #2 #3 #4  #5  Mean  #1 #2 #3  #4 #5  Mean 
Testis dimensions 
(L X W; sq mm) 
12.0 7.5  12.0 10.5  12.0  10.8 ± 
0.9 
5.0 5.0 5.0  5.0 6.0  5.2 ± 
0.2*** 
Seminiferous 
tubular atrophy/ 
degeneration 
(Score) 
Min. 
( 2.1) 
None 
( 1.1) 
None 
( 1.1) 
None 
( 1.1) 
None 
( 1.1) 
 
1.3 ± 
0.2 
Mod. 
(3.1) 
Mod. 
(3.1) 
Mod. 
(3.1) 
Mod. 
(3.1) 
Min. 
(2.1) 
 
2.9 ± 
0.2*** 
Leydig cell 
prominence 
(Score) 
Min. 
(2.1) 
WNL 
(1.1) 
 
WNL 
(1.1) 
 
WNL 
(1.1) 
 
WNL 
(1.1) 
 
 
1.3 + 
0.2 
Mod. 
(3.1) 
Mod. 
(3.1) 
Min. 
(2.1) 
Min. 
(2.1) 
WNL 
(1.1) 
 
2.3 + 
0.4* 
*P<0.05; ***P<0.001 
Mod. = Moderate 
Min. = Minimum 
WNL = Within Normal Limits Int. J. Environ. Res. Public Health 2009, 6          
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Figure 2.  Photomicrographs of testes histologies from: A) TSCM treated with 25 mg 
HU/kg; B) Control TSCM (Magnification bar = 200X); C) TSCM treated with 25 mg 
HU/kg; D) Control TSCM (Magnification bar = 400X). The TSCM treated with HU have 
degenerative/atrophic seminiferous tubules (ST) with only Sertoli cells (SC) and cellular 
debris remaining in the tubules compared with controls. Associated with the HU-induced 
changes in the seminiferous tubules are hyperplasia and cell prominence in the Leydig cell 
(L) compartment compared with controls. This indicates a reduction in spermatogenic 
activity and loss of fluid in the seminiferous tubules due to decreased testosterone 
production, hence the decrease in testis size. 
 
 
 
A. HU-treated TSCM (200X magnification)    
  
 
 
 
 
 
 
 
 
 
 
 
 
 
B. Control TSCM (200X magnification) 
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Figure 2. Cont. 
 
 
C. HU-treated TSCM (400X magnification) 
 
D. Control TSCM (400X magnification) 
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Figure 3. Effect of 25 mg HU/kg administered via oral gavage for 28 or 56 days on mean 
epididymal weight of TSCM; n = 6 per treatment or control group during the two time 
periods studied. Results are expressed as mean ± SE (HU = treated TSCM; Control = 
untreated TSCM). Asterisks indicate a significant difference from controls (P < 0.05). 
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Figure 4. Effect of HU (25 mg/kg, administered via oral gavage for 28 or 56 days) on 
mean stored sperm progressive motility of TSCM; n = 6 per treatment or control group 
during the two time period studied. Results are expressed as mean ± SE (HU = treated 
TSCM; Control = untreated TSCM). Asterisks indicate a significant difference from 
controls (P < 0.005). 
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Figure 5. Effect of HU (25 mg/kg, administered via oral gavage for 28 or 56 days) on 
mean stored sperm progressive motility of TSCM; n = 6 per treatment or control group 
during the two time periods studied. Results are expressed as mean ± SE (HU = treated 
TSCM; Control = untreated TSCM). Asterisks indicate a significant difference from 
controls (P < 0.005). 
 
Figure 6. Effect of HU on plasma testosterone concentrations in male TSCM treated by 
oral gavage with 25 mg HU/kg for 28 or 56 days; n = 6 per treatment or control group 
during the two time periods studied. Results are expressed as mean ± SE (HU = treated 
TSCM; Control = untreated TSCM). Asterisks indicate a significant difference from 
controls (P < 0.05). 
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4. Discussion 
 
In Experiment 1, we wanted to determine if adult male TCSM exhibit the pattern of reproductive 
endpoints that are characteristic of adult men with homozygous genes for SCD. In this experiment, we 
observed that testis weight was significantly reduced in TSCM compared with ICRM, indicating 
impairment in testicular exocrine function. In this experiment, we observed a significant reduction in 
the key spermatogenesis regulating hormone, testosterone, in TSCM versus ICRM, similar to the 
observation made by Modebe and Eze [6] among men with SCD compared with controls. Therefore 
the significant reduction in testis weight among TSCM versus ICRM can be explained by a reduction 
in spermatogenesis due to reduced testosterone synthesis and release [25] in as much as about 85% of 
the testis bulk is involved in spermatogenesis [25,32]. The observed reduction in testis weight and 
plasma testosterone concentrations among TSCM versus ICRM is indicative of hypogonadism, a 
condition that is inducible by SCD [6].  
Additionally, we observed a significant decrease in mean stored sperm density among TSCM versus 
ICRM, in agreement with the data reported by Modebe and Eze [6] in men with SCD compared with 
controls. This is likely due to SCD-induced reduction in testosterone-regulated spermatogenic and 
epididymal function of TSCM versus ICRM [6,25,32-33] resulting from the impairment of Leydig cell 
function by reactive oxygen species (ROS). The intermittent vascular occlusion occurring in SCD
  
[34-36]
 creates peripheral vascular insufficiency
 accompanied by periodic restoration of blood flow. 
This scenario places ischemic
 organs such as the testis and epididymis at risk of additional injury by 
inducing a proinflammatory
 state reflected by excessive generation of reactive oxygen species (ROS; 
super oxide, hydroxyl, nitric oxide, peroxide, peroxynitrile [37]). The latter has been shown to 
contribute to idiopathic male infertility [37].  
Interestingly, the presence of homozygous SCD genes was associated with a significant reduction in 
progressive motility among stored spermatozoa harvested from TSCM compared with ICRM and 
similar to observations made in patients with SCD [6]. Sperm progressive motility is positively 
correlated with fertilization of oocytes [38] and pregnancy rates [39], the decline of which is an 
indicator for impaired male gonadal function [40], a condition that is prevalent among patients with 
homozygous genes for SCD. Sickle cell disease-induced ROS [41] have been localized to several 
organs including the epididymis [42-46], the functions of which are compromised by these reactive 
molecules [47].  
Mature spermatozoa acquire the ability to move progressively during epididymal transit, a process 
that is regulated by testosterone and dihydrotestosterone (DHT; [48]). In Experiment 1, we observed a 
significant reduction in total plasma testosterone concentrations in TSCM compared with ICRM. This 
observation is significant because it suggests that the reduced sperm motility observed among TSCM 
is secondary to reduced epididymal exposure to physiological concentrations of androgens. It is also 
conceivable that excessive presence of ROS in the epididymides of TSCM compared with ICRM 
contributes to reduced sperm motility [49].  
Additionally, we observed a disproportionately higher percentage of spermatozoa with abnormal 
morphologies among stored spermatozoa recovered from TSCM versus ICRM, similar to the 
observation made in men with SCD compared with men with normal hemoglobin [6]. The reduction in 
the percentage of normal morphologic forms of spermatozoa in TSCM is attributable to ROS-induced Int. J. Environ. Res. Public Health 2009, 6          
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testosterone reduction [37]. If intra-testicular steroidogenesis is reduced substantially in TSCM, the 
level of testosterone reaching the epididymides from general circulation and testicular fluid may not be 
sufficient to optimally regulate the epididymides. This scenario could lead to a significant reduction in 
sperm maturation, survival and ultimately to the presence of degenerated spermatozoa in the cauda 
epididymides and vas deferens [33]. The increased percentage of abnormally shaped spermatozoa in 
the cauda epididymides of TSCM versus ICRM could be likened to the degenerating conditions of 
stored spermatozoa due to chronic deprivation of the epididymides of adequate testosterone. This is 
comparable to the situation found in seasonal-breeding animals at the time of testicular regression, 
when large numbers of semi-condensed spermatids and decapitated spermatozoa are present in the 
epididymis [50]. The results in this experiment on TSCM and those of others on SCD patients [6,51] 
suggest that inheritance of homozygous sickle cell genes results in inadequate functioning of the 
steroidogenic and spermatogenic compartments of the testis. Taken together, TSCM constitutes an 
authentic mouse model for studying the effect of HU on fertility indices of men with SCD.  
Hydroxyurea, at a dose range between 25 to 30 mg/kg used for the treatment of SCD [21], reduces 
the frequency of painful crisis in SCD patients by increasing the levels of fetal hemoglobin, which has 
a higher oxygen carrying capacity and does not undergo polymerization at low oxygen tension [7]. 
This SCD therapeutic agent is a potent inhibitor of the enzyme ribonucleotide
 reductase and inhibits 
DNA replication in a wide variety
 of cells [11] and therefore, has the ability to affect growth and 
function of organs that rely on DNA transcription, negatively. Interestingly, the mean body weight of 
HU-treated TSCM versus controls were comparable during the two time periods studied, in agreement 
with the finding that HU, at least at the dose range used for the treatment of SCD, does not limit 
weight gain among SCD patients [52,53]. However, we observed a significant reduction in testis 
weight among treated versus control mice at the two time periods studied. This observation is similar 
to that made by Kopsombut et al. [22] in adult ICRM treated with a clinically relevant dose of HU 
normally used for treating patients with SCD and indicates HU toxicity to the testis. The most 
vulnerable compartment of the testis to the toxic effects of xenobiotic agents is the spermatogenic 
compartment [25] that makes up approximately 85% of the testis bulk [32]. Consequently, a reduction 
in testis weight among treated TSCM suggests the suppression and or inhibition of spermatogenesis by 
HU. Based on available research data, HU can suppress spermatogenesis directly by arresting mitotic 
activity in spermatogonia through the inhibition of DNA synthesis [11,54].  However, it can also 
suppress spermatogenesis indirectly by repressing testosterone synthesis and release by Leydig cells 
[55]. For this to occur, HU must be metabolized by the liver to nitric oxide [56], a radical that has 
important consequences for the pathophysiology and treatment of SCD [57-60] albeit with a 
detrimental effect on a major spermatogenesis regulatory hormone, testosterone. The process of 
spermatogenesis is a testosterone-regulated process that occurs in waves along the length of the 
seminiferous tubules. It consists of mitotic proliferation and maintenance of spermatogonia 
(spermatocytogenesis) followed subsequently by meiotic divisions to insure genetic  diversity; and 
spermiogenesis for morphologic transformation of spermatids by the Sertoli cells to spermatozoa. 
Eventually, mature spermatozoa are detached from the Sertoli cells into the adluminal compartment of 
the seminiferous tubules during spermiation. Because HU has antimitotic property, the 40% reduction 
in testis weight among treated versus control TSCM on day 28 of treatment can be attributed to the 
suppression of spermatocytogenesis by HU in the sperm cycle that was initiated at the onset of HU Int. J. Environ. Res. Public Health 2009, 6          
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treatment. The additional 20% reduction in testis weight among treated versus control TSCM on day 
56 of treatment is attributable to the migration of spermatozoa whose development was initiated before 
and after HU treatment. It is noteworthy that the 56 days of HU treatment is greater than one sperm 
cycle (35.5 days in the mouse [29]). Therefore, it could be hypothesized that spermatids will not be 
apparent in the seminiferous tubules of treated TSCM versus their control counterparts if 
spermatogenesis is suppressed by HU from the onset of HU treatment. This hypothesis was proven to 
be true based on the absence of spermatids in most of the seminiferous tubules of HU-treated mice, in 
contrast with the presence of spermatids in the tubules of control mice (Figure 2).  
The 62-63% reduction in testis weight of treated versus control TSCM on day 56 of HU treatment 
was also contributed to by seminiferous tubular atrophy/degeneration which ultimately resulted in 
reduced testis dimensions (shrinkage). These observations are similar to those reported by Fiscor and 
Ginsberg [12], Evenson and Jost [13] and Wiger et al. [14] in HU-treated rodents and suggest that HU 
suppresses the spermatogenic process in the seminiferous tubules and causes degeneration of these 
tubules.  
Essentially, the mean epididymal weights of treated and control TSCM on day 28 of HU treatment 
were comparable due to the presence in this organ of mature spermatozoa whose development was 
initiated prior to HU treatment. However, due to HU-induced suppression of spermatogenesis during 
the 56 days of treatment (longer than one sperm cycle in the mouse [39]), it is conceivable that the 
reduced epididymal weight in treated TSCM versus controls may have resulted from fewer 
spermatozoa migrating into the epididymis.  
The decrease in epididymal weight among HU-treated versus control mice on day 56 of treatment 
was accompanied concomitantly by decreased stored sperm density and due to HU-induced reduction 
in sperm numbers transported into the epididymides post spermeation [61,62]. According to Plant and 
Marshall [63] and Archibong et al. [25], high intra-testicular testosterone concentrations are required 
for the regulation of spermatogenesis, the reduction of which results in fewer matured sperm produced 
for migration into the epididymis. Furthermore, the reduced concentrations of plasma testosterone 
among HU-treated TSCM compared with controls may have caused a rapid regression in the 
epididymal epithelium, especially in the initial segment and the proximal caput epididymal region 
[33]. Consequently, epididymal sperm maturation and survival were adversely affected and during the 
ensuing weeks, only a few degenerated spermatozoa remain in the cauda epididymides and vas 
deferens [33]. Thus, the reduced stored sperm density observed in this study may have been due to 
reduced spermatogenesis resulting from nitric oxide-induced reduction in testosterone synthesis and 
release [55]. 
Interestingly, treatment of TSCM with HU significantly reduced progressive motility among stored 
spermatozoa compared with that of their control counterparts in the second month of treatment, most 
likely due to the direct action of HU-induced nitric oxide. A correlation exists between high 
concentrations of nitric oxide in semen and reduced sperm motility. According to Balercia et al. [64], 
the concentrations of nitric oxide in semen samples of normozoospermic fertile men are significantly 
lower than those of their asthenozoospermic infertile counterparts.  
Mature spermatozoa acquire the ability to move progressively during epididymal transit, a process 
that is regulated by testosterone and dihydrotestosterone (DHT; [48]). In this study, we observed a 
significant reduction in total plasma testosterone in HU-treated compared with control TSCM during Int. J. Environ. Res. Public Health 2009, 6          
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the two time periods studied. However, reduced sperm motility was significantly observed only on day 
56 of the study in HU-treated TSCM versus controls. This is probably due to epididymal exposure to 
significantly high concentrations of nitric oxide and reduced testosterone by day 56 of testament in 
HU-treated TSCM.  
Altered morphological change (increased prominence) and hyperplasia were observed in Leydig 
cells of HU-treated TSCM compared with their control counterparts; however, it is not known whether 
the changes observed in Leydig cells from treated TSCM constitute a cause or effect of low 
testosterone synthesis in these mice.  
The interpretation of the significance of the changes observed in the Leydig cells of HU-treated 
TSCM is beset by the lack of knowledge of the precise stage at which HU-induced morphological 
changes occurred in relation to reduced testosterone biosynthesis. It is conceivable that the Leydig cell 
hyperplasia and altered prominence of this cell type in HU-treated TSCM are secondary to reduced 
testosterone biosynthesis. Similar changes in Leydig cells were observed in low testosterone producing 
transgenic mice overexpressing human aromatase by Li et al. [65]. Although the specific mechanism 
involved in the regulation of testosterone synthesis by HU is not examined in the present study, data 
generated by Lamanna et al. [55] indicate that nitric oxide, a metabolite of HU [56], is a suppressor of 
testosterone biosynthesis. The suppression of testosterone synthesis and release by the Leydig cells of 
HU-treated TSCM was progressive probably due to increased production of nitric oxide over the 
experimental time periods. It has been established that the inhibition of Leydig cell testosterone 
synthesis by nitric oxide is at select segments of the steroidogenesis pathway that does not involve the 
inhibition of LH receptor binding and induction steroidogenic acute regulatory protein (StAR) mRNA 
[66]. Rather, nitric oxide is effective in inhibiting testosterone biosynthesis after the synthesis of the 
first pro-steroid hormone (pregnenolone). It inhibits 3β-hydroxysteroid dehydrogenase (3β-HSD; [67]) 
and 17-hydroxylase/c17-20 lyase (P450c17; [67,68]); required for the conversion of pregnenolone to 
progesterone and the latter to androstenedione, respectively. Arguably, it calls to question whether the 
reversal of the inhibition of 3β-HSD and P450c17 in vivo can restore normal testosterone production 
by the Leydig cells of HU-treated TSCM and subsequently, the resumption of normal 
spermatogenesis. Kopsombut et al. [22] demonstrated that sperm motility was fully restored while 
spermatogenesis was partially restored (69%) in HU-treated ICRM compared with controls after four 
months treatment withdrawal. These data suggest that the activities of 3β-HSD and P450c17 were 
restored to permit the production of enough testosterone to fully restore sperm motility during 
epididymal transit but not enough to restore full spermatogenic activity. The partial restoration of 
spermatogenesis in HU-treated male mice was accompanied by significant fetal losses in females 
mated with these males compared to those mated to control males [22]. This observation indicates that 
the resumption of spermatogenesis four months post HU withdrawal does not necessary translate to the 
production of normal spermatozoa. It is conceivable that the fertilizing spermatozoa produced at the 
above mentioned period post HU withdrawal carry defective genes that contribute the high fetal 
mortality. Until research establishes a time-line for the production of normal spermatozoa post HU 
withdrawal, men anticipating a family should cryo-store their spermatozoa before submitting to HU 
treatment.  
The findings of our study strongly suggest that HU treatment exacerbated the condition of 
hypogonadism that is prevalent in patients with SCD. As a consequence, HU-treated TSCM suffered Int. J. Environ. Res. Public Health 2009, 6          
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testicular failure and reduced stored sperm density and motility compared with their control 
counterparts. Data presented in this study should raise awareness among adult male SCD patients 
considering a family to cryo-store their gametes prior to undergoing HU treatment due to the 
inconsistent data on return to normal reproductive function after treatment withdrawal.  
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